Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases

Cancer

Volumn 116, Issue 6, 2010, Pages 1510-1517

  Richards, William G ^a   Godleski, John J ^a   Yeap, Beow Y ^a,b   Corson, Joseph M ^a   Chirieac, Lucian R ^a   Zellos, Lambros ^a   Mujoomdar, Aneil ^a   Jaklitsch, Michael T ^a   Bueno, Raphael ^a   Sugarbaker, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diffuse malignant pleural mesothelioma; Epithelial mesothelioma; Extrapleural pneumonectomy; Pathologic staging; TNM staging

Indexed keywords

ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; EXTRAPLEURAL LIVER RESECTION; HUMAN; HUMAN TISSUE; LIVER RESECTION; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL TIME;

FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PLEURAL NEOPLASMS;

EID: 77949374950     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24886     Document Type: Article

References (21)

1. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. World Health Organization International Histological Classification of Tumours: Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin: Springer; 1999.
2. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over 2 decades, 1965-1985. J Clin Oncol. 1988;6:147-153.
3. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145-152.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-63; discussion 63-55.
5. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957-965.
6. Rusch V, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111:815-826.
7. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976;31:15-24.
8. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993;11:1172-1178.
9. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996;224:288-294.
10. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122-1128.
11. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
12. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
13. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788-795.
14. Lester SL. Manual of Surgical Pathology. Vol 2. Boston: Elsevier Churchill Livingstone; 2005:507-513.
15. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723.
16. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996;14:1-12.
17. AJCC Manual for staging of cancer. In: Beahrs OH, Hensen DE, Hutter RVP, Kennedy BJ, eds. 4th ed. Philadelphia: J.B. Lippincott; 1992.
18. Marchevsky AM, Folpe A, Amin MB. Thoracic mesothelium. Protocol applies to malignant thoracic mesothelioma. (January 2005 ed.): College of American Pathologists; 2005. Available at: http://www.cap.org/apps/docs/committees/ cancer/cancer-protocols/2005/thoracicmeso05-pw.pdf
19. Butnor KJ, Sporn TA, Ordonez NG. Recommendations for the reporting of pleural mesothelioma. Human Pathology. 2007;38:1587-1589.
20. Flores RM, Routledge T, Seshan VE, et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2008;136:605-610.
21. Schouwink JH, Kool LS, Rutgers EJ, et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg.75:1715- 1718,2003; discussion 1718-1719.